Abeona Therapeutics (NASDAQ:ABEO) Lowered to Sell Rating by StockNews.com

StockNews.com downgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a hold rating to a sell rating in a research note published on Thursday morning.

Several other equities analysts have also commented on the company. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research note on Monday, November 25th. Cantor Fitzgerald reiterated an “overweight” rating and set a $18.00 price objective on shares of Abeona Therapeutics in a report on Tuesday, October 29th.

Abeona Therapeutics Stock Down 0.7 %

ABEO stock opened at $5.96 on Thursday. The company has a 50 day moving average price of $5.97 and a two-hundred day moving average price of $5.64. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The stock has a market capitalization of $259.09 million, a P/E ratio of -2.22 and a beta of 1.46. Abeona Therapeutics has a one year low of $3.05 and a one year high of $9.01.

Institutional Investors Weigh In On Abeona Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new position in shares of Abeona Therapeutics in the 3rd quarter valued at about $84,000. Charles Schwab Investment Management Inc. acquired a new position in Abeona Therapeutics during the third quarter valued at approximately $151,000. XTX Topco Ltd purchased a new stake in Abeona Therapeutics during the third quarter worth approximately $160,000. JPMorgan Chase & Co. increased its position in shares of Abeona Therapeutics by 74.2% in the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock worth $424,000 after acquiring an additional 28,606 shares in the last quarter. Finally, GSA Capital Partners LLP increased its position in shares of Abeona Therapeutics by 54.3% in the third quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock worth $607,000 after acquiring an additional 33,831 shares in the last quarter. 80.56% of the stock is currently owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.